The purpose of the study was to evaluate safety, effects on platelet aggregation and pharmacokinetics of F(ab') 2 fragments of anti-glycoprotein (GP) IIb-IIIa murine monoclonal antibody FRaMon (F(ab') 2 FRaMon) upon its intravenous administration in patients undergoing high-risk coronary angioplasty. Patients were treated before angioplasty with F(ab') 2 FRaMon at 0.2 mg/kg ( n = 17) and 0.25 mg/kg ( n = 12) bolus or with abciximab at 0.25 mg/kg bolus + 12 h infusion at 0.125 w g/kg per min ( n = 29). F(ab') 2 FRaMon at both doses decreased platelet aggregation induced by 20 w M ADP to 95, 70-80 and 40-50% of GP IIb-IIIa at 1 and 12-24 h and 3 days after injection, respectively. Thrombotic complications within the first month after angioplasty in groups treated with F(ab') 2 FRaMon and abciximab were observed in one and two patients, respectively. The data obtained have shown that F(ab') 2 FRaMon at bolus administration to patients undergoing coronary angioplasty caused no serious side effects and at comparative dosage inhibited platelet aggregation with the same efficacy as abciximab at bolus + infusion administration.
16 April 2018 in Bulletin of Experimental Biology and Medicine
SUMMARY: 1. In the present study, we sought to determine whether patients with restenosis after coronary stenting possess increased monocyte reactivity, as manifested by a higher level of adhesion molecule expression and an enhanced propensity to form monocyte–platelet aggregates after activation in vitro.2. Anti‐coagulated peripheral venous blood from 24 patients, 10 with and 14 without angiographically verified restenosis, was obtained. Leucocyte antigen expression and the number of leucocyte–platelet complexes were measured by flow cytometry after activation in whole blood.3. Surface integrin Mac‐1 (CD11b/CD18) and VLA‐4 (CD49d/ CD29) expression on monocytes and the relative number of monocyte–platelet complexes after in vitro activation were significantly elevated in patients with restenosis compared with patients without restenosis (fluorescence intensities of 1425 ± 76 vs 1195 ± 71, 87 ± 7 vs 65 ± 6 and 47 ± 4 vs 29 ± 3% for for Mac‐1, VLA‐4 and monocyte–platelet complexes, respectively; P < 0.05 for each parameter).4. The results suggest that restenosis is associated with increased monocyte VLA‐4 and Mac‐1 integrin expression and monocyte–platelet complex formation, which can be revealed after activation in vitro.
Measurement of neopterin in biological fluids is a sensitive and specific tool for detecting activation of the T cell/macrophage system. Serum neopterin level, detected by radioimmunoassay, and data from morphological investigations of myocardium were compared in 29 patients with a clinical diagnosis of dilated heart muscle disease. According to the results of endomyocardial biopsy (22 cases) and autopsy (seven cases), 14 patients had morphological features of myocarditis, 13 dilated cardiomyopathy and two a fibrotic subtype of dilated cardiomyopathy (DCMP). The mean neopterin level in all patients (12±9nM−1) was higher than in the control group (5±2nm−1) (P<07middot;05). Also, the mean neopterin level was significantly higher in patients with myocarditis and fibrotic subtype of DCMP (16±11 nM l−1) than in patients with a morphological diagnosis of DCMP (9±6nM l−1) (P<0·05). The highest neopterin levels in both groups were found in those who subsequently died during follow-up (mean level 23±10nM l−1). There was a correlation between neopterin and β2-microglobulin (r = 0·83, P<0·05). Our study suggests that the raised serum neopterin level may be a marker of myocardial inflammation and unfavourable prognosis in patients with a clinical diagnosis of dilated heart muscle disease.